<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="a0c17202-de1b-4a3c-9b0f-e7a68767b6e4"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE TABLETS  safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE TABLETS .<br/>
      <br/>METFORMIN HYDROCHLORIDE tablets, for oral use<br/>Initial U.S. Approval: 1995<br/>
   </title>
   <effectiveTime value="20191206"/>
   <setId root="c82a10fa-1e8e-46b6-890a-737de3f34ee1"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="156861945" root="1.3.6.1.4.1.519.1"/>
            <name>Zydus Pharmaceuticals (USA) Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="156861945" root="1.3.6.1.4.1.519.1"/>
                  <name>Zydus Pharmaceuticals (USA) Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="918596198" root="1.3.6.1.4.1.519.1"/>
                        <name>Cadila Healthcare Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-758" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-759" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-760" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-758" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-759" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-760" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="863362789" root="1.3.6.1.4.1.519.1"/>
                        <name>Cadila Healthcare Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-758" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-759" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-760" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-758" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-759" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68382-760" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2d07b36a-4f06-410a-bad2-422a2512ffd8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20191206"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68382-758" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METFORMIN HYDROCHLORIDE</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METFORMIN HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METFORMIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-758-16" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-758-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-758-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-758-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-758-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68382-758-77" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20141209"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203686" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20141209"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>WHITE TO OFF-WHITE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>ROUND</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="13" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">70;Z</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68382-759" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METFORMIN HYDROCHLORIDE</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METFORMIN HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="850" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METFORMIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-759-16" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-759-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-759-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-759-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-759-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68382-759-77" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20141209"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203686" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20141209"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>WHITE TO OFF-WHITE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">69;Z</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68382-760" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METFORMIN HYDROCHLORIDE</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METFORMIN HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1000" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METFORMIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-760-16" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-760-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-760-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-760-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20141209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68382-760-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68382-760-77" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20141209"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203686" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20141209"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>WHITE TO OFF-WHITE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="2"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Z;71</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID419">
               <id root="15d5fadd-250d-41ce-908f-b1693682132c"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: LACTIC ACIDOSIS</title>
               <text>
                  <paragraph ID="ID421">
                     <content styleCode="bold">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin- associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin- associated lactic acidosis was characterized by elevated blood lactate levels (&gt;5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally &gt;5 mcg/mL [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)</content>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see <content styleCode="italics">Dosage and Administration (<linkHtml href="#ID246">2.3</linkHtml>), (2.7), Contraindications (<linkHtml href="#ID268">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)</content>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)</content>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID422">
                           <content styleCode="bold">WARNING: LACTIC ACIDOSIS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID423" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Postmarketing cases of metformin-associated      lactic acidosis have      resulted in death, hypothermia, hypotension, and      resistant bradyarrhythmias. Symptoms included malaise,      myalgias,      respiratory distress, somnolence,      and abdominal pain. Laboratory      abnormalities included elevated blood lactate      levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally      &gt;5 mcg/mL. (<linkHtml href="#ID274">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Risk factors include renal impairment,      concomitant use of certain drugs, age &gt;65 years old, radiological      studies with contrast, surgery and other procedures, hypoxic states,      excessive alcohol intake, and hepatic impairment. Steps to reduce the risk      of and manage metforminassociated lactic acidosis in these high risk      groups are provided in the Full Prescribing Information.      (<linkHtml href="#ID274">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">If lactic acidosis is suspected, discontinue      metformin hydrochloride tablets and institute general supportive measures      in a hospital setting. Prompt hemodialysis is recommended.      (<linkHtml href="#ID274">5.1</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID234">
               <id root="69176a74-f2bf-41fd-bbdc-35f27115d3b5"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID235">Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.</paragraph>
               </text>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID237">Metformin hydrochloride tablets are biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. (<linkHtml href="#ID234">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID238">
               <id root="5271d605-a854-40f5-bc05-8355f2b2b9d1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID251">
                           <content styleCode="bold">
                              <content styleCode="italics">Adult Dosage for Metformin Hydrochloride Tablets:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID252" styleCode="Disc">
                           <item>Starting dose: 500 mg orally twice a day or 850      mg once a day, with meals (<linkHtml href="#ID239">2.1</linkHtml>)</item>
                           <item>Increase the dose in increments of 500 mg weekly      or 850 mg every 2 weeks, up to a maximum dose of 2,550 mg per day, given      in divided doses (<linkHtml href="#ID239">2.1</linkHtml>)</item>
                           <item>Doses above 2,000 mg may be better tolerated      given 3 times a day with meals (<linkHtml href="#ID239">2.1</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID255">
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatric Dosage for Metformin Hydrochloride Tablets: </content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID256" styleCode="Disc">
                           <item>Starting dose: 500 mg      orally      twice a      day, with meals (<linkHtml href="#ID244">2.2</linkHtml>)</item>
                           <item>Increase dosage      in increments of 500 mg weekly up to      a maximum of 2,000 mg      per      day, given in      divided doses twice daily (<linkHtml href="#ID244">2.2</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID257">
                           <content styleCode="bold">
                              <content styleCode="italics">Renal Impairment:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID258" styleCode="Disc">
                           <item>Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (<linkHtml href="#ID246">2.3</linkHtml>)<list listType="unordered" styleCode="Circle">
                                 <item>Do not use in patients with eGFR below 30 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID246">2.3</linkHtml>)</item>
                                 <item>Initiation is not recommended in patients with eGFR between 30 mL/minute/1.73 m<sup>2</sup>to 45 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID246">2.3</linkHtml>)</item>
                                 <item>Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID246">2.3</linkHtml>)</item>
                                 <item>Discontinue if eGFR falls below 30 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID246">2.3</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                        <paragraph ID="ID259">
                           <content styleCode="bold">
                              <content styleCode="italics">Discontinuation for Iodinated Contrast Imaging Procedures:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID260" styleCode="Disc">
                           <item>Metformin hydrochloride tablets may need to be      discontinued at time of, or prior to, iodinated contrast imaging      procedures (<linkHtml href="#ID248">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID239">
                     <id root="d0f7bcaf-1c5d-493f-8c6f-cd4572f84986"/>
                     <title>2.1 Adult Dosage</title>
                     <text>
                        <paragraph ID="ID240">
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Tablets</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID241" styleCode="Disc">
                           <item> The recommended starting dose of metformin hydrochloride tablets are 500 mg orally twice a day or 850 mg once a day, given with meals.</item>
                           <item> Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks on the basis of glycemic control and tolerability, up to a maximum dose of 2,550 mg per day, given in divided doses.</item>
                           <item> Doses above 2,000 mg may be better tolerated given 3 times a day with meals.</item>
                        </list>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID244">
                     <id root="6c622d79-f4c0-478a-b6b5-7754b0db4baf"/>
                     <title>2.2 Pediatric Dosage for Metformin Hydrochloride Tablets</title>
                     <text>
                        <list listType="unordered" ID="ID245" styleCode="Disc">
                           <item> The recommended starting dose of metformin hydrochloride tablets for pediatric patients 10 years of age and older is 500 mg orally twice a day, given with meals.</item>
                           <item> Increase dosage in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg per day, given in divided doses twice daily.</item>
                        </list>
                     </text>
                     <effectiveTime value="20180619"/>
                  </section>
               </component>
               <component>
                  <section ID="ID246">
                     <id root="89108860-3008-456c-9f1a-b05afe1b8f5d"/>
                     <title>2.3 Recommendations for Use in Renal Impairment</title>
                     <text>
                        <list listType="unordered" ID="ID247" styleCode="Disc">
                           <item> Assess renal function prior to initiation of metformin hydrochloride tablets and periodically thereafter.</item>
                           <item> Metformin hydrochloride tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m<sup>2</sup>.</item>
                           <item> Initiation of metformin hydrochloride tablets in patients with an eGFR between 30 mL/minute/1.73 m<sup>2</sup>to 45 mL/minute/1.73 m<sup>2</sup>is not recommended.</item>
                           <item> In patients taking metformin hydrochloride tablets whose eGFR later falls below 45 mL/min/1.73 m<sup>2</sup>, assess the benefit risk of continuing therapy.</item>
                           <item> Discontinue metformin hydrochloride tablets if the patient's eGFR later falls below 30 mL/minute/1.73 m<sup>2</sup>[see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)</content> ].</item>
                        </list>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID248">
                     <id root="7afeeed4-ccc3-444b-aeae-12f6bb69ef49"/>
                     <title>2.4 Discontinuation for Iodinated Contrast Imaging Procedures</title>
                     <text>
                        <paragraph ID="ID249">Discontinue metformin hydrochloride tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m<sup>2</sup>; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra- arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride tablets if renal function is stable.</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID261">
               <id root="f1648c1d-d45c-4007-a6a0-e9eeda145402"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID262">
                     <content styleCode="bold">
                        <content styleCode="italics">Metformin Hydrochloride Tablets, USP</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" ID="ID263" styleCode="Disc">
                     <item> Metformin Hydrochloride Tablets USP, 500 mg are white to off-white, round shaped, film-coated tablets debossed with the logo of "70" on one side and "Z" on the other side.</item>
                     <item> Metformin Hydrochloride Tablets USP, 850 mg are white to off-white, oval shaped, film-coated tablets debossed with the logo of "69" on one side and "Z" on the other side.</item>
                     <item> Metformin Hydrochloride Tablets USP, 1,000 mg are white to off-white, oval shaped, biconvex, film-coated tablets with bisect on both the sides; one side of the bisect is debossed with "Z" and other side of the bisect is debossed with "71".</item>
                  </list>
               </text>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID425" styleCode="Disc">
                           <item>Metformin      hydrochloride tablets: 500 mg, 850 mg, and 1,000 mg      (<linkHtml href="#ID261">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID268">
               <id root="72de1f3d-2212-4413-a373-f441793ba201"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID269">Metformin hydrochloride tablets are contraindicated in patients with:</paragraph>
                  <list listType="unordered" ID="ID270" styleCode="Disc">
                     <item> Severe renal impairment (eGFR below 30 mL/min/1.73 m<sup>2</sup>) [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)</content> ].</item>
                     <item> Hypersensitivity to metformin.</item>
                     <item> Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.</item>
                  </list>
               </text>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID272" styleCode="Disc">
                           <item>Severe renal      impairment (eGFR below 30      mL/min/1.73      m<sup>2</sup>) (<linkHtml href="#ID268">4</linkHtml>, <linkHtml href="#ID274">5.1</linkHtml>)</item>
                           <item>Hypersensitivity      to metformin (<linkHtml href="#ID268">4</linkHtml>)</item>
                           <item>Acute or chronic      metabolic acidosis, including diabetic ketoacidosis, with      or without      coma. (<linkHtml href="#ID268">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID273">
               <id root="cb5778c4-8ceb-4aab-af0c-8b159306a74b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID426" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Lactic      Acidosis:</content> See boxed warning.      (<linkHtml href="#ID274">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Vitamin B12      Deficiency:</content> Metformin may lower vitamin B12      levels. Measure hematological parameters annually and vitamin B12 at 2 to      3 year intervals and manage any abnormalities.      (<linkHtml href="#ID293">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia      with Concomitant Use with Insulin and Insulin Secretagogues:</content> Increased risk of hypoglycemia when used in combination with      insulin and/or an insulin secretagogue. Lower dose of insulin or insulin      secretagogue may be required (<linkHtml href="#ID295">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID274">
                     <id root="e7002063-1259-4317-ad43-315bbacd2500"/>
                     <title>5.1 Lactic Acidosis</title>
                     <text>
                        <paragraph ID="ID275">There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin- associated lactic acidosis was characterized by elevated blood lactate concentrations (&gt;5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels were generally &gt;5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.</paragraph>
                        <paragraph>If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of metformin hydrochloride tablets. In metformin hydrochloride tablets treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.</paragraph>
                        <paragraph>Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue metformin hydrochloride tablets and report these symptoms to their healthcare provider.</paragraph>
                        <paragraph>For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:</paragraph>
                        <list listType="unordered" ID="ID276" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Renal impairment: </content> The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment.  The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient's renal function include [see <content styleCode="italics">Dosage and Administration (<linkHtml href="#ID239">2.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID345">12.3</linkHtml>)</content> ]:<list listType="unordered" styleCode="Circle">
                                 <item>Before initiating metformin hydrochloride tablets, obtain an estimated glomerular filtration rate (eGFR).</item>
                                 <item>Metformin hydrochloride tablets are contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2 [see Contraindications (<linkHtml href="#ID268">4</linkHtml>)].</item>
                                 <item>Initiation of metformin hydrochloride tablets is not recommended in patients with eGFR between 30 mL/min/1.73 m2 to 45 mL/min/1.73 m2.</item>
                                 <item>Obtain an eGFR at least annually in all patients taking metformin hydrochloride tablets. In patients at risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently.</item>
                                 <item>In patients taking metformin hydrochloride tablets whose eGFR falls below 45 mL/min/1.73 m2, assess the benefit and risk of continuing therapy.</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="italics">Drug interactions</content> : The concomitant use of metformin hydrochloride tablets with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation. Consider more frequent monitoring of patients.</item>
                           <item>
                              <content styleCode="italics">Age 65 or greater: </content> The risk of metformin-associated lactic acidosis increases with the patient's age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients.</item>
                           <item>
                              <content styleCode="italics">Radiologic studies with contrast : </content> Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop metformin hydrochloride tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 mL/min/1.73 m<sup>2</sup>and 60 mL/min/1.73 m<sup>2</sup>; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart metformin hydrochloride tablets if renal function is stable.</item>
                           <item>
                              <content styleCode="italics">Surgery and other procedures: </content> Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension, and renal impairment. Metformin hydrochloride tablets should be temporarily discontinued while patients have restricted food and fluid intake.</item>
                           <item>
                              <content styleCode="italics">Hypoxic states: </content> Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may cause prerenal azotemia. When such an event occurs, discontinue metformin hydrochloride tablets.</item>
                           <item>
                              <content styleCode="italics">Excessive alcohol intake: </content> Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving metformin hydrochloride tablets.</item>
                           <item>
                              <content styleCode="italics">Hepatic impairment: </content> Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of metformin hydrochloride tablets in patients with clinical or laboratory evidence of hepatic disease.</item>
                        </list>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID293">
                     <id root="cfc75c4e-7c0f-4dc8-9a73-f00e44afe98e"/>
                     <title>5.2 Vitamin B12 Deficiency</title>
                     <text>
                        <paragraph ID="ID294">In metformin hydrochloride tablets clinical trials of 29 week duration, a decrease to subnormal levels of previously normal serum vitamin B<sub>12</sub> levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B<sub>12</sub> absorption from the B<sub>12</sub>-intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of Metformin hydrochloride tablets or vitamin B<sub>12</sub> supplementation. Certain individuals (those with inadequate vitamin B<sub>12</sub> or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B<sub>12</sub> levels. Measure hematologic parameters on an annual basis and vitamin B<sub>12</sub> at 2 to 3 year intervals in patients on metformin hydrochloride tablets and manage any abnormalities [see <content styleCode="italics">Adverse Reactions (<linkHtml href="#ID304">6.1</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID295">
                     <id root="b90ce03b-aee6-4b4c-9a76-6d2d4456d028"/>
                     <title>5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues</title>
                     <text>
                        <paragraph ID="ID296">Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Metformin hydrochloride tablets may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with metformin hydrochloride tablets <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID314">7</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID297">
                     <id root="d277e014-3735-4a0e-be6c-d543d3453422"/>
                     <title>5.4 Macrovascular Outcomes</title>
                     <text>
                        <paragraph ID="ID298">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin hydrochloride tablets.</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID301">
               <id root="f6636ad5-560d-49dc-a509-5dfeca0233be"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID302">The following adverse reactions are also discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered" ID="ID303" styleCode="Disc">
                     <item> Lactic Acidosis <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)]</content>
                     </item>
                     <item> Vitamin B<sub>12</sub>Deficiency <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID293">5.2</linkHtml>)]</content>
                     </item>
                     <item> Hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID295">5.3</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID313">For Metformin hydrochloride tablets, the most common adverse reactions (&gt;5.0%) are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache. (<linkHtml href="#ID304">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID304">
                     <id root="c39552bd-cfe9-481e-8c1b-d66ddc2fb5e3"/>
                     <title>6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph ID="ID305">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Tablets</content>
                           </content>
                        </paragraph>
                        <paragraph>In a U.S. clinical trial of metformin hydrochloride tablets in patients with type 2 diabetes mellitus, a total of 141 patients received metformin hydrochloride tablets up to 2,550 mg per day. Adverse reactions reported in greater than 5% of metformin hydrochloride tablets treated patients and that were more common than in placebo-treated patients, are listed in Table 1.</paragraph>
                        <table ID="ID306" width="624" styleCode="Noautorules">
                           <caption>  Table 1 Adverse Reactions from a Clinical Trial of Metformin Hydrochloride Tablets Occurring &gt;5% and More Common than Placebo in Patients with Type 2 Diabetes Mellitus </caption>
                           <col width="208"/>
                           <col width="208"/>
                           <col width="208"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride Tablets </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=141)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=145)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 53%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 12%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nausea/Vomiting<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 26%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Flatulence<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 12%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Asthenia<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 9%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Indigestion<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abdominal Discomfort<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID307">Diarrhea led to discontinuation of metformin hydrochloride tablets in 6% of patients. Additionally, the following adverse reactions were reported in 1% to 5% of metformin hydrochloride tablets treated patients and were more commonly reported with metformin hydrochloride tablets than placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation.</paragraph>
                        <paragraph>In metformin hydrochloride tablets clinical trials of 29 week duration, a decrease to subnormal levels of previously normal serum vitamin B<sub>12</sub> levels was observed in approximately 7% of patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>In clinical trials with metformin hydrochloride tablets in pediatric patients with type 2 diabetes mellitus, the profile of adverse reactions was similar to that observed in adults.</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID310">
                     <id root="d743628a-ad3c-4f42-9974-b2d4228ef6d6"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID311">The following adverse reactions have been identified during post approval use of metformin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.</paragraph>
                     </text>
                     <effectiveTime value="20180619"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID314">
               <id root="0369c520-2002-4db8-89b1-6575b297fb06"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID315">Table 3 presents clinically significant drug interactions with metformin hydrochloride tablets.</paragraph>
                  <table ID="ID316" width="0" styleCode="Noautorules">
                     <caption>  Table 3 Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets </caption>
                     <col width="110"/>
                     <col width="516"/>
                     <tbody>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Carbonic Anhydrase Inhibitors</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider more frequent monitoring of these patients.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Examples:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Topiramate, zonisamide, acetazolamide or dichlorphenamide.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Drugs that Reduce Metformin Hydrochloride Tablets Clearance</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID345">12.3</linkHtml>)].</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider the benefits and risks of concomitant use with metformin hydrochloride tablets.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Examples:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Ranolazine, vandetanib, dolutegravir, and cimetidine.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Alcohol</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Alcohol is known to potentiate the effect of metformin on lactate metabolism.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Warn patients against excessive alcohol intake while receiving metformin hydrochloride tablets.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Insulin Secretagogues or Insulin</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Coadministration of metformin hydrochloride tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Drugs Affecting Glycemic Control</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> When such drugs are administered to a patient receiving metformin hydrochloride tablets, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride tablets, observe the patient closely for hypoglycemia.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Examples:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID427" styleCode="Disc">
                           <item>Carbonic      anhydrase inhibitors may increase risk of lactic acidosis. Consider more      frequent monitoring (<linkHtml href="#ID314">7</linkHtml>)</item>
                           <item>Drugs that      reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir,      and cimetidine) may increase the accumulation of metformin. Consider the      benefits and risks of concomitant use (<linkHtml href="#ID314">7</linkHtml>)</item>
                           <item>Alcohol can      potentiate the effect of metformin on lactate metabolism. Warn patients      against excessive alcohol intake (<linkHtml href="#ID314">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID319">
               <id root="a82694b7-01da-4407-8013-341697a7122b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20181227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID335" styleCode="Disc">
                           <item>Females and Males of Reproductive Potential: Advise premenopausal females      of the potential      for an      unintended pregnancy.      (<linkHtml href="#ID324">8.3</linkHtml>)</item>
                           <item>Geriatric Use:      Assess renal function      more frequently. (<linkHtml href="#ID328">8.5</linkHtml>)</item>
                           <item>Hepatic Impairment:      Avoid use in      patients      with hepatic impairment.      (<linkHtml href="#ID332">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID320">
                     <id root="47277700-552c-4a0e-87bb-75b7c6f0f0d2"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID321">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited data with metformin hydrochloride tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk <content styleCode="italics">[see Data]. </content>There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy <content styleCode="italics">[see Clinical Considerations].</content>
                        </paragraph>
                        <paragraph>No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2 times and 5 times, respectively, a 2,550 mg clinical dose, based on body surface area <content styleCode="italics">[see Data].</content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes mellitus with an HbA1C &gt;7 and has been reported to be as high as 20% to 25% in women with a HbA1C &gt;10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Clinical Considerations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Data</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Published data from postmarketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Metformin hydrochloride did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 times and 5 times a 2,550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID322">
                     <id root="1affcaf9-4cbb-46e0-bbfa-d7714c786b27"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID323">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited published studies report that metformin is present in human milk <content styleCode="italics">[see Data]. </content>However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metformin hydrochloride and any potential adverse effects on the breastfed child from metformin hydrochloride tablets or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID324">
                     <id root="0a2d3e22-5889-4250-ba45-b8072936a132"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph ID="ID325">Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin hydrochloride tablets may result in ovulation in some anovulatory women.</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID326">
                     <id root="1336fee3-aa67-4576-be6f-1e951354559f"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID327">
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Tablets</content>
                           </content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of metformin hydrochloride tablets for the treatment of type 2 diabetes mellitus have been established in pediatric patients 10 years to 16 years old. Safety and effectiveness of metformin hydrochloride tablets have not been established in pediatric patients less than 10 years old.</paragraph>
                        <paragraph>Use of metformin hydrochloride tablets in pediatric patients 10 years to 16 years old for the treatment of type 2 diabetes mellitus is supported by evidence from adequate and well-controlled studies of metformin hydrochloride tablets in adults with additional data from a controlled clinical study in pediatric patients 10 years to 16 years old with type 2 diabetes mellitus, which demonstrated a similar response in glycemic control to that seen in adults <content styleCode="italics">[see Clinical Studies (14.1)]</content>. In this study, adverse reactions were similar to those described in adults. A maximum daily dose of 2,000 mg of metformin hydrochloride tablets are recommended. [See <content styleCode="italics">Dosage and Administration (2.2)</content>.]</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID328">
                     <id root="5b0b0be9-da1e-4ca5-a853-fb0c86153311"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID329">Controlled clinical studies of metformin hydrochloride tablets did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients [see <content styleCode="italics">Warnings and Precautions (5.1)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID330">
                     <id root="c194447c-188e-4d11-b186-4bcb9c4e0475"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID331">Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Metformin hydrochloride tablets are contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m<sup>2</sup> [see <content styleCode="italics">Dosage and Administration (2.3), Contraindications (4), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID332">
                     <id root="74007914-ecb2-4dc1-9739-9b0f9e1968aa"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID333">Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Metformin hydrochloride tablets are not recommended in patients with hepatic impairment. [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID336">
               <id root="dd82f7cc-43fc-4ffc-a949-01e47a064fdd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID337">Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)</content>]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.</paragraph>
               </text>
               <effectiveTime value="20180619"/>
            </section>
         </component>
         <component>
            <section ID="ID338">
               <id root="0cc34879-a4ca-45f9-bca9-b8d2fef8b757"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID339">Metformin hydrochloride tablets contain the antihyperglycemic agent metformin, which is a biguanide, in the form of monohydrochloride. The chemical name of metformin hydrochloride is <content styleCode="italics">N,N</content>-dimethylimidodicarbonimidic diamide hydrochloride. The structural formula is as shown below:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID341">Metformin hydrochloride, USP is a white crystalline powder with a molecular formula of C<sub>4</sub>H<sub>11</sub>N<sub>5</sub>  HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water, slightly soluble in alcohol and is practically insoluble in acetone and methylene chloride. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.</paragraph>
                  <paragraph>Metformin hydrochloride tablets, USP contain 500 mg or 850 mg or 1,000 mg of metformin hydrochloride, USP. Each tablet contains the inactive ingredients colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and sodium starch glycolate.</paragraph>
                  <paragraph>The methodology used for dissolution testing is USP Test 1 for metformin hydrochloride tablets, USP.</paragraph>
               </text>
               <effectiveTime value="20181227"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="077b6725-d723-44e4-b050-dd384b218063-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID342">
               <id root="5299c638-cf23-4ff5-861c-6ff006597bd4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20181227"/>
               <component>
                  <section ID="ID343">
                     <id root="4e42ea96-662e-44f0-ad1e-7ff7391c02f3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID344">Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.</paragraph>
                     </text>
                     <effectiveTime value="20180619"/>
                  </section>
               </component>
               <component>
                  <section ID="ID345">
                     <id root="4f33d97d-8eae-4100-8f15-faf71d9663be"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID346">
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>The absolute bioavailability of metformin hydrochloride tablets, 500 mg given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin hydrochloride tablets 500 mg to 1,500 mg and 850 mg to 2,550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. At usual clinical doses and dosing schedules of metformin hydrochloride tablets, steady state plasma concentrations of metformin are reached within 24 hours to 48 hours and are generally &lt;1 g/mL.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of food: </content>
                        </paragraph>
                        <paragraph>Food decreases the extent of absorption and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C<sub>max</sub>), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T<sub>max</sub>) following administration of a single 850 mg tablet of metformin hydrochloride tablets with food, compared to the same tablet strength administered fasting.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride tablets 850 mg averaged 654  358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Elimination</content>
                           </content>
                        </paragraph>
                        <paragraph>Renal clearance (see Table 4) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Renal Impairment</content>
                           </content>
                        </paragraph>
                        <paragraph>In patients with decreased renal function the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased (see Table 3) [See <content styleCode="italics">Dosage and Administration (<linkHtml href="#ID246">2.3</linkHtml>), Contraindications (<linkHtml href="#ID268">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID330">8.6</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatic </content>Impairment</content>
                        </paragraph>
                        <paragraph>No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment [See <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID332">8.7</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Geriatrics</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited data from controlled pharmacokinetic studies of metformin hydrochloride tablets in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C<sub>max</sub> is increased, compared to healthy young subjects. It appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 4). [See <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>) </content>and <content styleCode="italics">Use in Specific Populations (<linkHtml href="#ID328">8.5</linkHtml>)</content>].</paragraph>
                        <table ID="ID347" width="624" styleCode="Noautorules">
                           <caption>  Table 4 Select Mean (S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin Hydrochloride Tablets </caption>
                           <col width="318"/>
                           <col width="102"/>
                           <col width="90"/>
                           <col width="114"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> All doses given fasting except the first 18 doses of the multiple dose studies</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Peak plasma concentration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> Time to peak plasma concentration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>d</sup> Combined results (average means) of five studies: mean age 32 years (range 23 years to59 years)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>e</sup> Kinetic study done following dose 19, given fasting</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>f</sup> Elderly subjects, mean age 71 years (range 65 years to 81 years)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>g</sup> CL<sub>cr</sub>= creatinine clearance normalized to body surface area of 1.73 m<sup>2</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Subject Groups: Metformin Hydrochloride Tabletsdose<sup>a</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (number of subjects)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                       <sup>b</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (mcg/mL)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> T</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                       <sup>c</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (hrs)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Renal Clearance</content>
                                    <br/>
                                    <content styleCode="bold"> (mL/min)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Healthy, nondiabetic adults:</content>
                                    <br/> 500 mg single dose (24)<br/> 850 mg single dose (74)<sup>d</sup>
                                    <br/> 850 mg three times daily for 19 doses<sup>e</sup> (9)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.03 (0.33)<br/> 1.60 (0.38)<br/> 2.01 (0.42)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.75 (0.81)<br/> 2.64 (0.82)<br/> 1.79 (0.94)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 600 (132)<br/> 552 (139)<br/> 642 (173)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Adults with type 2 diabetes mellitus:</content>
                                    <br/> 850 mg single dose (23)<br/> 850 mg three times daily for 19 doses<sup>e</sup> (9)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.48 (0.5)<br/> 1.90 (0.62)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.32 (1.08)<br/> 2.01 (1.22)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 491 (138)<br/> 550 (160)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Elderly</content>
                                    <sup>f</sup>
                                    <content styleCode="bold"> , healthy nondiabetic adults:</content>
                                    <br/> 850 mg single dose (12)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.45 (0.70)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.71 (1.05)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 412 (98)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Renal-impaired adults:</content>
                                    <br/>
                                    <content styleCode="bold"> 850 mg single dose</content>
                                    <br/>
                                    <content styleCode="bold"> Mild </content> (CL<sub>cr</sub>
                                    <sup>g</sup>61 mL/min to 90 mL/min) (5)<br/>
                                    <content styleCode="bold"> Moderate </content> (CL<sub>cr</sub> 31 mL/min to 60 mL/min) (4)<br/>
                                    <content styleCode="bold"> Severe </content> (CL<sub>cr </sub>10 mL/min to 30 mL/min) (6)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.86 (0.52)<br/> 4.12 (1.83)<br/> 3.93 (0.92)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.20 (0.45)<br/> 3.75 (0.50)<br/> 4.01 (1.10)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 384 (122)<br/> 108 (57)<br/> 130 (90)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID348">
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatrics</content>
                           </content>
                        </paragraph>
                        <paragraph>After administration of a single oral metformin hydrochloride tablets500 mg tablet with food, geometric mean metformin C<sub>max</sub> and AUC differed less than 5% between pediatric type 2 diabetic patients (12 years to 16 years of age) and gender- and weight-matched healthy adults (20 years to 45 years of age), all with normal renal function.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gender</content>
                           </content>
                        </paragraph>
                        <paragraph>Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes mellitus when analyzed according to gender (males=19, females=16).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Race</content>
                           </content>
                        </paragraph>
                        <paragraph>No studies of metformin pharmacokinetic parameters according to race have been performed.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">In Vivo</content><content styleCode="italics">Assessment of Drug Interactions</content>
                           </content>
                        </paragraph>
                        <table ID="ID349" width="100%" styleCode="Noautorules">
                           <caption>  Table 5 Effect of Coadministered Drug on Plasma Metformin Systemic Exposure </caption>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>*</sup> All metformin and coadministered drugs were given as single doses</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup></sup> AUC = AUC(INF)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup></sup> Ratio of arithmetic means</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup></sup> At steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC<sub>0 to 12h</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule Botrule" align="center">
                                    <content styleCode="bold"> Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug<sup>*</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of</content>
                                    <br/>
                                    <content styleCode="bold"> Metformin<sup>*</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Geometric Mean Ratio</content>
                                    <br/>
                                    <content styleCode="bold"> (ratio with/without coadministered drug) No Effect = 1.00</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC</content>
                                    <sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> No dosing adjustments required for the following:</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.91<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.93<sup></sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.09<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.22<sup></sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.16<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.21<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.90<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.94<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.05<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.07<sup></sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination </content> [See <content styleCode="italics">W</content>
                                    <content styleCode="italics">arnings and Precautions (5.9) </content> and <content styleCode="italics">Drug Interactions (7.2).</content> ]<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.40<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.61<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Carbonic anhydrase inhibitors may cause metabolic acidosis </content> [See <content styleCode="italics">Warnings and Precautions (5.1) </content> and <content styleCode="italics">Drug Interactions (7.1).</content> ]<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Topiramate<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 100 mg<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 500 mg<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.25<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.17<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID350" width="634" styleCode="Noautorules">
                           <caption>  Table 6 Effect of Metformin on Coadministered Drug Systemic Exposure </caption>
                           <col width="120"/>
                           <col width="163"/>
                           <col width="100"/>
                           <col width="94"/>
                           <col width="88"/>
                           <col width="69"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>*</sup> All metformin and coadministered drugs were given as single doses</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup></sup> AUC = AUC(INF) unless otherwise noted</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup></sup> Ratio of arithmetic means, p-value of difference &lt;0.05</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup></sup> AUC(0hr to 24 hr) reported</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup></sup> Ratio of arithmetic means</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule Botrule" align="center">
                                    <content styleCode="bold"> Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of</content>
                                    <br/>
                                    <content styleCode="bold"> Coadministered Drug</content>
                                    <sup>*</sup>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of</content>
                                    <br/>
                                    <content styleCode="bold"> Metformin</content>
                                    <sup>*</sup>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Geometric Mean Ratio (ratio with/without metformin) </content>
                                    <br/>
                                    <content styleCode="bold"> No Effect = 1</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC</content>
                                    <sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> No dosing adjustments required for the following:</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.78<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.63<sup></sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.87<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.69<sup></sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.10<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.08<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.02<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.97<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<sup></sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.95<sup></sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID351">
               <id root="bf639b05-1bf8-4e37-8827-7e8da1378869"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20180619"/>
               <component>
                  <section ID="ID352">
                     <id root="e697c080-5a05-49ea-a570-16ddc0c48c53"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID353">Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1,500 mg/kg/day, respectively. These doses are both approximately 3 times the maximum recommended human daily dose of 2,550 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.</paragraph>
                        <paragraph>There was no evidence of a mutagenic potential of metformin in the following <content styleCode="italics">in vitro </content>tests: Ames test (<content styleCode="italics">S. typhimurium</content>), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the <content styleCode="italics">in vivo </content>mouse micronucleus test were also negative.</paragraph>
                        <paragraph>Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 2 times the maximum recommended human daily dose of 2,550 mg based on body surface area comparisons.</paragraph>
                     </text>
                     <effectiveTime value="20180619"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID354">
               <id root="18872c83-5e94-43a9-a2b3-d95fb05303bf"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20181227"/>
               <component>
                  <section ID="ID355">
                     <id root="76e62968-7b1b-49a4-abeb-dcd7daecca5f"/>
                     <title>14.1 Metformin Hydrochloride Tablets</title>
                     <text>
                        <paragraph ID="ID356">
                           <content styleCode="bold">
                              <content styleCode="italics">Adult Clinical Studies</content>
                           </content>
                        </paragraph>
                        <paragraph>A double-blind, placebo-controlled, multi-center US clinical trial involving obese patients with type 2 diabetes mellitus whose hyperglycemia was not adequately controlled with dietary management alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL) was conducted. Patients were treated with metformin hydrochloride (up to 2,550 mg/day) or placebo for 29 weeks. The results are presented in Table 7.</paragraph>
                        <table ID="ID357" width="625" styleCode="Noautorules">
                           <caption>  Table 7 Mean Change in Fasting Plasma Glucose and HbA1c at Week 29 Comparing Metformin Hydrochloride Tablets vs. Placebo in Patients with Type 2 Diabetes Mellitus </caption>
                           <col width="250"/>
                           <col width="125"/>
                           <col width="125"/>
                           <col width="125"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>* </sup>Not statistically significant</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride Tablets</content>
                                    <br/>
                                    <content styleCode="bold"> (n=141)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> (n=145)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> p-Value</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> FPG (mg/dL)</content>
                                    <br/> Baseline<br/> Change at FINAL VISIT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 241.5<br/> 53.0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 237.7<br/> 6.3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NS<sup>*</sup>
                                    <br/> 0.001<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Hemoglobin A1c (%)</content>
                                    <br/> Baseline<br/> Change at FINAL VISIT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.4<br/> 1.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.2<br/> 0.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NS<sup>*</sup>
                                    <br/> 0.001<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID358">Mean baseline body weight was 201 lbs and 206 lbs in the metformin hydrochloride and placebo arms, respectively. Mean change in body weight from baseline to week 29 was -1.4 lbs and -2.4 lbs in the metformin hydrochloride and placebo arms, respectively. A 29 week, double-blind, placebo-controlled study of metformin hydrochloride and glyburide, alone and in combination, was conducted in obese patients with type 2 diabetes mellitus who had failed to achieve adequate glycemic control while on maximum doses of glyburide (baseline FPG of approximately 250 mg/dL). Patients randomized to the combination arm started therapy with metformin hydrochloride 500 mg and glyburide 20 mg. At the end of each week of the first 4 weeks of the trial, these patients had their dosages of metformin hydrochloride increased by 500 mg if they had failed to reach target fasting plasma glucose. After week 4, such dosage adjustments were made monthly, although no patient was allowed to exceed metformin hydrochloride 2,500 mg. Patients in the metformin hydrochloride only arm (metformin plus placebo) discontinued glyburide and followed the same titration schedule. Patients in the glyburide arm continued the same dose of glyburide. At the end of the trial, approximately 70% of the patients in the combination group were taking metformin hydrochloride 2,000 mg/glyburide 20 mg or metformin hydrochloride 2,500 mg/glyburide 20 mg. The results are displayed in Table 8.</paragraph>
                        <table ID="ID359" width="624" styleCode="Noautorules">
                           <caption>  Table 8 Mean Change in Fasting Plasma Glucose and HbA1c at Week 29 Comparing Metformin Hydrochloride/Glyburide (Comb) vs. Glyburide (Glyb) vs. Metformin Hydrochloride (GLU): in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Glyburide </caption>
                           <col width="246"/>
                           <col width="66"/>
                           <col width="66"/>
                           <col width="66"/>
                           <col width="60"/>
                           <col width="60"/>
                           <col width="60"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>* </sup>Not statistically significant</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Comb</content>
                                    <br/>
                                    <content styleCode="bold"> (n=213)</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Glyb</content>
                                    <br/>
                                    <content styleCode="bold"> (n=209)</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> GLU (n=210)</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> p-Values</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Glyb vs. Comb</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> GLU vs. Comb</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> GLU vs. Glyb</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Fasting Plasma Glucose (mg/dL)</content>
                                    <br/> Baseline<br/> Change at FINAL VISIT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 250.5<br/> 63.5<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 247.5<br/> 13.7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 253.9<br/> 0.9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NS<sup>*</sup>
                                    <br/> 0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NS<sup>*</sup>
                                    <br/> 0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NS<sup>*</sup>
                                    <br/> 0.025<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Hemoglobin A1c (%)</content>
                                    <br/> Baseline<br/> Change at FINAL VISIT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.8<br/> 1.7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.5<br/> 0.2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.9<br/> 0.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NS<sup>*</sup>
                                    <br/> 0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NS<sup>*</sup>
                                    <br/> 0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.007<br/> 0.001<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID360">Mean baseline body weight was 202 lbs, 203 lbs, and 204 lbs in the metformin hydrochloride/glyburide, glyburide, and metformin hydrochloride arms, respectively. Mean change in body weight from baseline to week 29 was 0.9 lbs, -0.7 lbs, and -8.4 lbs in the metformin hydrochloride/glyburide, glyburide, and metformin hydrochloride arms, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatric Clinical Studies</content>
                           </content>
                        </paragraph>
                        <paragraph>A double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with type 2 diabetes mellitus (mean FPG 182.2 mg/dL), treatment with metformin hydrochloride (up to 2,000 mg/day) for up to 16 weeks (mean duration of treatment 11 weeks) was conducted. The results are displayed in Table 9.</paragraph>
                        <table ID="ID361" width="625" styleCode="Noautorules">
                           <caption>  Table 9 Mean Change in Fasting Plasma Glucose at Week 16 Comparing Metformin Hydrochloride vs. Placebo in Pediatric Patients<sup>a</sup> with Type 2 Diabetes Mellitus </caption>
                           <col width="250"/>
                           <col width="125"/>
                           <col width="125"/>
                           <col width="125"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>a </sup>Pediatric patients mean age 13.8 years (range 10 years to 16 years)</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> p-Value</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left">
                                    <content styleCode="bold"> FPG (mg/dL)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center">
                                    <content styleCode="bold"> (n=37)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center">
                                    <content styleCode="bold"> (n=36)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Baseline<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 162.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 192.3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Change at FINAL VISIT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 42.9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 21.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID362">Mean baseline body weight was 205 lbs and 189 lbs in the metformin hydrochloride and placebo arms, respectively. Mean change in body weight from baseline to week 16 was -3.3 lbs and -2.0 lbs in the metformin hydrochloride and placebo arms, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20180703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID369">
               <id root="bdb0112c-9e4a-4ce8-ad71-b68e37cc4145"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20181227"/>
               <component>
                  <section ID="ID370">
                     <id root="e2a893c4-565b-4665-a0c0-2ce09b8524ee"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph ID="ID371">
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Tablets, USP</content>
                           </content>
                        </paragraph>
                        <paragraph>Metformin Hydrochloride Tablets USP, 500 mg are white to off-white, round shaped, film-coated tablets debossed with the logo of "70" on one side and "Z" on the other side and are supplied as follows.</paragraph>
                        <paragraph>NDC 68382-758-16 in bottles of 90 tablets</paragraph>
                        <paragraph>NDC 68382-758-01 in bottles of 100 tablets</paragraph>
                        <paragraph>NDC 68382-758-05 in bottles of 500 tablets</paragraph>
                        <paragraph>NDC 68382-758-10 in bottles of 1,000 tablets</paragraph>
                        <paragraph>NDC 68382-758-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets</paragraph>
                        <paragraph>Metformin Hydrochloride Tablets USP, 850 mg are white to off-white, oval shaped, film-coated tablets debossed with the logo of "69" on one side and "Z" on the other side and are supplied as follows.</paragraph>
                        <paragraph>NDC 68382-759-16 in bottles of 90 tablets</paragraph>
                        <paragraph>NDC 68382-759-01 in bottles of 100 tablets</paragraph>
                        <paragraph>NDC 68382-759-05 in bottles of 500 tablets</paragraph>
                        <paragraph>NDC 68382-759-10 in bottles of 1,000 tablets</paragraph>
                        <paragraph>NDC 68382-759-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets</paragraph>
                        <paragraph>Metformin Hydrochloride Tablets USP, 1,000 mg are white to off-white, oval shaped, biconvex, film-coated tablets with bisect on both the sides; one side of the bisect is debossed with "Z" and other side of the bisect is debossed with "71" and are supplied as follows.</paragraph>
                        <paragraph>NDC 68382-760-16 in bottles of 90 tablets</paragraph>
                        <paragraph>NDC 68382-760-01 in bottles of 100 tablets</paragraph>
                        <paragraph>NDC 68382-760-05 in bottles of 500 tablets</paragraph>
                        <paragraph>NDC 68382-760-10 in bottles of 1,000 tablets</paragraph>
                        <paragraph>NDC 68382-760-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets</paragraph>
                     </text>
                     <effectiveTime value="20181227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID372">
                     <id root="9d6924f1-319a-4333-9ee7-13b38c080483"/>
                     <title>16.2 Storage</title>
                     <text>
                        <paragraph ID="ID373">Store at 20 to 25C (68to 77F) [See USP Controlled Room Temperature].</paragraph>
                        <paragraph>Dispense in light-resistant containers.</paragraph>
                     </text>
                     <effectiveTime value="20180619"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID374">
               <id root="d5d9dfd3-e47b-4001-80ec-52da1a27f23a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID375">Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Lactic Acidosis</content>
                  </paragraph>
                  <paragraph>Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue metformin hydrochloride tablets immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving metformin hydrochloride tablets. Instruct patients to inform their doctor that they are taking metformin hydrochloride tablets prior to any surgical or radiological procedure, as temporary discontinuation may be required <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID274">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypoglycemia</content>
                  </paragraph>
                  <paragraph>Inform patients that hypoglycemia may occur when metformin hydrochloride tablets are coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID295">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Vitamin </content>
                     <content styleCode="italics">B<sub>12</sub> Deficiency</content>
                  </paragraph>
                  <paragraph>Inform patients about importance of regular hematological parameters while receiving metformin hydrochloride tablets <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID293">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Females of Reproductive Age</content>
                  </paragraph>
                  <paragraph>Inform females that treatment with metformin hydrochloride tablets may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID324">8.3</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20181227"/>
            </section>
         </component>
         <component>
            <section ID="ID376">
               <id root="2e11dbe4-4e1d-4f13-aff9-fd06f09e1faa"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID377">
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cadila Healthcare Ltd.</content>
                  </paragraph>
                  <paragraph>Ahmedabad, India</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Pharmaceuticals (USA) Inc.</content>
                  </paragraph>
                  <paragraph>Pennington, NJ 08534</paragraph>
                  <paragraph>Rev.: 12/18</paragraph>
               </text>
               <effectiveTime value="20181227"/>
            </section>
         </component>
         <component>
            <section ID="ID378">
               <id root="47072977-a79a-4e43-a5a2-d53da5ba9e2d"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph ID="ID379">
                     <content styleCode="bold">PATIENT INFORMATION </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin Hydrochloride (met for' min hye'' droe klor' ide) Tablets, USP</content>
                  </paragraph>
                  <paragraph>Read the Patient Information that comes with metformin hydrochloride tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about metformin hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Serious side effects can happen in people taking metformin hydrochloride tablets, including:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lactic Acidosis. </content>Metformin hydrochloride, the medicine in metformin hydrochloride tablets, can cause a rare, but serious, side effect called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in a hospital.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Stop taking metformin hydrochloride tablets and call your healthcare provider right away if you get any of the following symptoms of lactic acidosis:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID380" styleCode="Disc">
                     <item>feel very weak and tired</item>
                     <item>have unusual (not normal)      muscle pain</item>
                     <item>have trouble breathing</item>
                     <item>have unusual sleepiness      or sleep longer than usual</item>
                     <item>have unexplained      stomach or      intestinal      problems      with nausea and      vomiting, or diarrhea</item>
                     <item>feel cold, especially in your      arms and      legs</item>
                     <item>feel dizzy or      lightheaded</item>
                     <item>have a slow      or irregular      heartbeat</item>
                  </list>
                  <paragraph ID="ID381">
                     <content styleCode="bold">You have a higher chance of getting lactic acidosis if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID382" styleCode="Disc">
                     <item>have kidney problems.      People whose kidneys are not      working properly should not take metformin hydrochloride tablets.</item>
                     <item>have liver problems.</item>
                     <item>have congestive      heart failure that requires treatment with      medicines.</item>
                     <item>drink a lot of      alcohol      (very often or short-term "binge" drinking).</item>
                     <item>get dehydrated (lose a large amount of body fluids).      This can      happen if you are sick with a fever,      vomiting, or diarrhea. Dehydration      can also happen when      you sweat a lot with activity      or exercise      and do      not drink      enough fluids.</item>
                     <item>have certain x-ray tests with injectable      dyes or contrast agents.</item>
                     <item>have surgery.</item>
                     <item>have a heart      attack,      severe infection,      or stroke.</item>
                     <item>are 80 years      of age or older and have      not had your kidney function      tested.</item>
                  </list>
                  <paragraph ID="ID383">
                     <content styleCode="bold">What are metformin hydrochloride tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID384" styleCode="Disc">
                     <item>Metformin hydrochloride tablets are prescription      medicines      that contain      metformin hydrochloride.      Metformin      hydrochloride are      used with      diet and exercise      to help control high blood sugar (hyperglycemia)      in adults with type      2 diabetes.</item>
                     <item>Metformin hydrochloride      tablets are not      for people      with type 1      diabetes.</item>
                     <item>Metformin hydrochloride      tablets are not for people with diabetic      ketoacidosis (increased ketones      in your blood or      urine).</item>
                  </list>
                  <paragraph ID="ID385">Metformin hydrochloride tablets help control your blood sugar in a number of ways. These include helping your body respond better to the insulin it makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of sugar your intestines absorb. Metformin hydrochloride tablets do not cause your body to make more insulin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take metformin hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Some conditions increase your chance of getting lactic acidosis, or cause other problems if you take either of these medicines. Most of the conditions listed below can increase your chance of getting lactic acidosis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take metformin hydrochloride tablets if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID386" styleCode="Disc">
                     <item>have kidney problems</item>
                     <item>are allergic to the metformin hydrochloride in metformin hydrochloride tablets</item>
                     <item>or any of the      ingredients      in metformin      hydrochloride tablets. See the end of this leaflet for a complete list of ingredients in metformin hydrochloride tablets.</item>
                     <item>are going      to get an injection of dye or contrast agents for an x-ray      procedure      or if you are going to have      surgery and not      able to eat      or drink      much. In these situations, metformin hydrochloride tablets will need to be stopped      for a short time. Talk to      your healthcare provider      about when you should stop      metformin      hydrochloride tablets and when you should start metformin hydrochloride tablets again.      See "<content styleCode="bold">What is      the most important      information I      should know      about metformin      hydrochloride tablets?</content> "</item>
                  </list>
                  <paragraph ID="ID387">
                     <content styleCode="bold">What should I tell my healthcare provider before taking metformin hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Before taking metformin hydrochloride tablets, tell your healthcare provider if you:</paragraph>
                  <list listType="unordered" ID="ID388" styleCode="Disc">
                     <item>have type      1 diabetes. Metformin hydrochloride tablets should not be used to treat people with type 1      diabetes.</item>
                     <item>have a history or      risk for diabetic ketoacidosis      (high levels of certain      acids, known      as ketones,      in the blood or      urine).      Metformin      hydrochloride tablets should not be used for      the treatment of diabetic      ketoacidosis.</item>
                     <item>have kidney problems.</item>
                     <item>have liver problems.</item>
                     <item>have heart problems,      including congestive      heart failure.</item>
                     <item>are older than 80 years. If you are over 80      years old you      should not      take metformin hydrochloride      tablets unless your      kidneys have been      checked and they are normal.</item>
                     <item>drink alcohol very      often, or      drink a      lot of      alcohol in short-term      "binge" drinking.</item>
                     <item>are taking      insulin.</item>
                     <item>have any other medical      conditions.</item>
                     <item>are pregnant      or plan      to become pregnant.      It is not known if metformin hydrochloride tablets will harm      your unborn baby. If you are      pregnant, talk with      your healthcare provider      about the      best way      to control      your blood sugar while you      are pregnant.</item>
                     <item>are breast-feeding      or plan to      breast-feed.      It is not      known if      metformin      hydrochloride passes into your breast milk. Talk with your      healthcare provider about the best way to feed your      baby while you      take metformin hydrochloride tablets.</item>
                  </list>
                  <paragraph ID="ID389">
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and nonprescription medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <list listType="unordered" ID="ID390" styleCode="Disc">
                     <item>Metformin hydrochloride tablets may affect      the way other medicines      work, and other medicines      may affect      how metformin hydrochloride tablets works.</item>
                  </list>
                  <paragraph ID="ID391">
                     <content styleCode="bold">Can metformin hydrochloride tablets be used in children?</content>
                  </paragraph>
                  <paragraph>Metformin hydrochloride tablets have been shown to effectively lower glucose levels in children (ages 10 years to 16 years) with type 2 diabetes. Metformin hydrochloride tablets have not been studied in children younger than 10 years old. Metformin hydrochloride tablets have not been studied in combination with other oral glucose-control medicines or insulin in children. If you have any questions about the use of metformin hydrochloride tablets in children, talk with your doctor or other healthcare provider.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take metformin hydrochloride tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID392" styleCode="Disc">
                     <item>Take metformin      hydrochloride tablets exactly as your healthcare      provider      tells you.</item>
                     <item>Metformin hydrochloride tablets should be taken with meals to      help lessen an upset stomach side effect.</item>
                     <item>Swallow metformin      hydrochloride tablets whole.</item>
                     <item>When your body is      under some types of stress, such      as fever, trauma (such as a car accident),      infection, or surgery, the      amount of diabetes medicine      that you need may change. Tell your healthcare      provider right away      if you have any of these problems.</item>
                     <item>Your healthcare provider      should do      blood tests to      check how      well your      kidneys      are working before      and during      your treatment with metformin hydrochloride tablets.</item>
                     <item>Your healthcare provider      will check your diabetes      with regular blood tests, including your      blood sugar levels      and your      hemoglobin A1C.</item>
                     <item>Follow your healthcare provider's instructions for treating      blood sugar that is too low (hypoglycemia). Talk to your healthcare provider      if low blood sugar is a problem for you.      See "<content styleCode="bold">What are the possible      side effects      of metformin hydrochloride      tablets?</content> "</item>
                     <item>Check your blood sugar as your healthcare provider tells you      to.</item>
                     <item>Stay on your      prescribed      diet and exercise      program while      taking metformin      hydrochloride tablets.</item>
                     <item>If you miss a dose      of metformin hydrochloride tablets, take      your next dose      as prescribed unless your healthcare provider tells you differently.      Do not take      an extra dose      the next      day.</item>
                     <item>If you take too      much metformin      hydrochloride tablets, call      your healthcare      provider, local      Poison Control Center, or go to the nearest hospital emergency room right away.</item>
                  </list>
                  <paragraph ID="ID393">
                     <content styleCode="bold">What should I avoid while taking metformin hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Do not drink a lot of alcoholic drinks while taking metformin hydrochloride tablets. This means you should not binge drink for short periods, and you should not drink a lot of alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the side effects of metformin hydrochloride tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID394" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Lactic acidosis. Metformin, the active ingredient in metformin hydrochloride tablets, can      cause a rare      but serious condition called lactic acidosis (a buildup of      an acid in the      blood) that      can cause death. Lactic acidosis is a medical emergency and must      be treated in the      hospital.</content>
                     </item>
                  </list>
                  <paragraph ID="ID395">Call your doctor right away if you have any of the following symptoms, which could be signs of lactic acidosis:</paragraph>
                  <list listType="unordered" ID="ID396" styleCode="Disc">
                     <item>you feel cold in      your hands or feet</item>
                     <item>you feel      dizzy or lightheaded</item>
                     <item>you have a slow or irregular      heartbeat</item>
                     <item>you feel very weak or tired</item>
                     <item>you have trouble breathing</item>
                     <item>you feel sleepy or drowsy</item>
                     <item>you have stomach pains, nausea or vomiting</item>
                  </list>
                  <paragraph ID="ID397">Most people who have had lactic acidosis with metformin have other things that, combined with the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, because you have a higher chance for getting lactic acidosis with metformin hydrochloride tablets if you:</paragraph>
                  <list listType="unordered" ID="ID398" styleCode="Disc">
                     <item>have severe      kidney problems, or your      kidneys      are affected      by certain x-ray tests that use injectable dye</item>
                     <item>have liver problems</item>
                     <item>drink alcohol      very often, or drink      a lot of alcohol      in short-term "binge" drinking</item>
                     <item>get dehydrated (lose      a large amount of body      fluids).      This can      happen if you      are sick      with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot      with activity or      exercise      and do not drink enough fluids</item>
                     <item>have surgery</item>
                     <item>have a heart attack, severe infection,      or stroke</item>
                  </list>
                  <paragraph ID="ID399">Common side effects of metformin hydrochloride tablets include diarrhea, nausea, and upset stomach. These side effects generally go away after you take the medicine for a while. Taking your medicine with meals can help reduce these side effects. Tell your doctor if the side effects bother you a lot, last for more than a few weeks, come back after they've gone away, or start later in therapy. You may need a lower dose or need to stop taking the medicine for a short period or for good.</paragraph>
                  <paragraph>About 3 out of every 100 people who take metformin hydrochloride tablets have an unpleasant metallic taste when they start taking the medicine. It lasts for a short time.</paragraph>
                  <paragraph>Metformin hydrochloride tablets rarely cause hypoglycemia (low blood sugar) by themselves. However, hypoglycemia can happen if you do not eat enough, if you drink alcohol, or if you take other medicines to lower blood sugar.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store metformin hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Store metformin hydrochloride tablets at 20 to 25C (68 to 77F).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep metformin hydrochloride tablets and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the use of metformin hydrochloride tablets </content>
                  </paragraph>
                  <paragraph>If you have questions or problems, talk with your doctor or other healthcare provider. You can ask your doctor or pharmacist for the information about metformin hydrochloride tablets that is written for healthcare professionals. Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use metformin hydrochloride tablets for a condition for which it was not prescribed. Do not share your medicine with other people.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients of metformin hydrochloride tablets?</content>
                  </paragraph>
                  <paragraph>Active ingredients of metformin hydrochloride tablets: metformin hydrochloride, USP.</paragraph>
                  <paragraph>Inactive ingredients in each tablet of metformin hydrochloride tablets: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and sodium starch glycolate.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is type 2 diabetes?</content>
                  </paragraph>
                  <paragraph>Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems. </paragraph>
                  <paragraph>The main goal of treating diabetes is to lower your blood sugar to a normal level. High blood sugar can be lowered by diet and exercise, and by certain medicines when necessary.</paragraph>
                  <paragraph>Talk to your healthcare provider about how to prevent, recognize, and take care of low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), and problems you have because of your diabetes.</paragraph>
                  <paragraph>Other brands listed are the trademarks of their respective owners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20181224"/>
            </section>
         </component>
         <component>
            <section ID="ID400">
               <id root="448f1918-72cd-44f1-814a-ac79758853e4"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID401">
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cadila Healthcare Ltd.</content>
                  </paragraph>
                  <paragraph>Ahmedabad, India.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Pharmaceuticals (USA) Inc.</content>
                  </paragraph>
                  <paragraph>Pennington, NJ 08534.</paragraph>
                  <paragraph>Rev.: 12/18</paragraph>
               </text>
               <effectiveTime value="20181227"/>
            </section>
         </component>
         <component>
            <section ID="ID402">
               <id root="feeeaa80-97fd-4ecc-8312-e3be5cbe0bc1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID405">NDC 68382-758-01 in bottle of 100 tablets</paragraph>
                  <paragraph>Metformin Hydrochloride Tablets USP, 500 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 tablets</paragraph>
                  <paragraph>ZYDUS</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID409">NDC 68382-759-01 in bottle of 100 tablets</paragraph>
                  <paragraph>Metformin Hydrochloride Tablets USP, 850 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 tablets</paragraph>
                  <paragraph>ZYDUS</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID413">NDC 68382-760-01 in bottle of 100 tablets</paragraph>
                  <paragraph>Metformin Hydrochloride Tablets USP, 1000 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 tablets</paragraph>
                  <paragraph>ZYDUS</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20181227"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="077b6725-d723-44e4-b050-dd384b218063-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="077b6725-d723-44e4-b050-dd384b218063-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="077b6725-d723-44e4-b050-dd384b218063-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>